PL1912640T3 - Zastosowanie inhibitora HDAC panobinostatu w leczeniu szpiczaka - Google Patents

Zastosowanie inhibitora HDAC panobinostatu w leczeniu szpiczaka

Info

Publication number
PL1912640T3
PL1912640T3 PL06789025T PL06789025T PL1912640T3 PL 1912640 T3 PL1912640 T3 PL 1912640T3 PL 06789025 T PL06789025 T PL 06789025T PL 06789025 T PL06789025 T PL 06789025T PL 1912640 T3 PL1912640 T3 PL 1912640T3
Authority
PL
Poland
Prior art keywords
myeloma
treatment
hdac inhibitor
inhibitor panobinostat
panobinostat
Prior art date
Application number
PL06789025T
Other languages
English (en)
Inventor
Peter W Atadja
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37307336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1912640(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL1912640T3 publication Critical patent/PL1912640T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL06789025T 2005-08-03 2006-08-01 Zastosowanie inhibitora HDAC panobinostatu w leczeniu szpiczaka PL1912640T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70522605P 2005-08-03 2005-08-03
EP06789025.1A EP1912640B1 (en) 2005-08-03 2006-08-01 Use of the hdac inhibitor panobinostat for the treatment of myeloma
PCT/US2006/029801 WO2007019116A1 (en) 2005-08-03 2006-08-01 Use of hdac inhibitors for the treatment of myeloma

Publications (1)

Publication Number Publication Date
PL1912640T3 true PL1912640T3 (pl) 2015-11-30

Family

ID=37307336

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06789025T PL1912640T3 (pl) 2005-08-03 2006-08-01 Zastosowanie inhibitora HDAC panobinostatu w leczeniu szpiczaka

Country Status (18)

Country Link
US (2) US20080221126A1 (pl)
EP (1) EP1912640B1 (pl)
JP (2) JP5665271B2 (pl)
KR (1) KR101354237B1 (pl)
CN (2) CN104324025A (pl)
AU (1) AU2006278718B2 (pl)
BR (1) BRPI0614090A2 (pl)
CA (1) CA2617274C (pl)
DK (1) DK1912640T3 (pl)
ES (1) ES2545076T3 (pl)
HU (1) HUE028025T2 (pl)
LT (1) LTC1912640I2 (pl)
MX (1) MX2008001610A (pl)
PL (1) PL1912640T3 (pl)
PT (1) PT1912640E (pl)
RU (1) RU2420279C3 (pl)
SI (1) SI1912640T1 (pl)
WO (1) WO2007019116A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019116A1 (en) * 2005-08-03 2007-02-15 Novartis Ag Use of hdac inhibitors for the treatment of myeloma
BRPI0807812A2 (pt) * 2007-02-15 2020-06-23 Novartis Ag Combinações de lbh589 com outros agentes terapêuticos para tratar câncer
DK2162129T3 (da) * 2007-05-30 2019-06-11 Novartis Ag Anvendelse af hdac-hæmmere til behandling af knogledestruktion
WO2010075286A1 (en) * 2008-12-24 2010-07-01 University Of Washington MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY
KR20130101519A (ko) * 2010-09-01 2013-09-13 노파르티스 아게 Ｈｄａｃ 억제제와 혈소판감소증 약물의 조합물
MA41544A (fr) * 2015-02-19 2017-12-26 Novartis Ag Dosages de panobinostat pour le traitement du myélome multiple
EP3371195B1 (en) 2015-11-03 2021-04-21 Hochschule Darmstadt Selective hdac8 inhibitors and their uses
CN105348169B (zh) * 2015-11-16 2018-03-30 青岛大学 一种组蛋白去乙酰酶抑制剂(e)‑3‑(2‑(1‑(4‑氯苯甲酰基)‑5‑甲氧基‑2‑甲基‑1氢‑吲哚‑3‑基)乙酰氨基)‑n‑羟基丁‑2‑烯酰胺及其制备方法和应用
CN109705057B (zh) * 2017-10-25 2023-05-30 成都先导药物开发股份有限公司 组蛋白去乙酰化酶抑制剂及其制备方法与用途
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
WO2020018778A1 (en) 2018-07-18 2020-01-23 Surender Kharbanda Polymeric nanoparticles comprising salinomycin
WO2022251844A1 (en) 2021-05-25 2022-12-01 Hillstream Biopharma, Inc. Polymeric nanoparticles comprising chemotherapeutic compounds and related methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DK1392313T3 (da) * 2001-05-16 2007-06-25 Novartis Ag Kombination omfattende N-{5-[4-(4-methyl-piperazino-methyl)-benzoyl-amido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidin-amin og et biphosphonat
WO2003048774A1 (en) * 2001-12-07 2003-06-12 Novartis Ag Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20070123580A1 (en) * 2003-05-21 2007-05-31 Atadja Peter W Combination of histone deacetylase inhibitors with chemotherapeutic agents
CN1964714B (zh) * 2003-08-29 2011-09-28 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸和吉西他滨在制备用于治疗癌症的药物中的用途
EP3354265A1 (en) 2005-03-22 2018-08-01 President and Fellows of Harvard College Treatment of solid tumors
WO2007019116A1 (en) * 2005-08-03 2007-02-15 Novartis Ag Use of hdac inhibitors for the treatment of myeloma

Also Published As

Publication number Publication date
JP2013173757A (ja) 2013-09-05
KR101354237B1 (ko) 2014-01-22
JP5665271B2 (ja) 2015-02-04
US20100160257A1 (en) 2010-06-24
MX2008001610A (es) 2008-02-19
JP5876435B2 (ja) 2016-03-02
SI1912640T1 (sl) 2015-10-30
LTC1912640I2 (lt) 2017-09-11
AU2006278718B2 (en) 2010-10-07
BRPI0614090A2 (pt) 2011-03-09
HUE028025T2 (en) 2016-11-28
RU2008107871A (ru) 2009-09-10
EP1912640A1 (en) 2008-04-23
PT1912640E (pt) 2015-09-22
RU2420279C2 (ru) 2011-06-10
CA2617274A1 (en) 2007-02-15
KR20080031937A (ko) 2008-04-11
EP1912640B1 (en) 2015-06-17
CN101232880A (zh) 2008-07-30
DK1912640T3 (en) 2015-09-14
AU2006278718A1 (en) 2007-02-15
RU2420279C3 (ru) 2017-03-14
CA2617274C (en) 2017-10-10
WO2007019116A1 (en) 2007-02-15
US8883842B2 (en) 2014-11-11
US20080221126A1 (en) 2008-09-11
JP2009503087A (ja) 2009-01-29
ES2545076T3 (es) 2015-09-08
CN104324025A (zh) 2015-02-04

Similar Documents

Publication Publication Date Title
PL1912640T3 (pl) Zastosowanie inhibitora HDAC panobinostatu w leczeniu szpiczaka
AP2870A (en) Odcase inhibitors for the treatment of malaria
IL183938A0 (en) Amino - imidazolones for the inhibition of ?? - becretase
HK1124320A1 (en) Sulphonylpyrroles as inhibitors of hdac s novel sulphonylpyrroles
HRP20130810T1 (en) Sulphonylpyrroles as hdac inhibitors
LT2295410T (lt) Hdac inhibitorius
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
EP1898834A4 (en) SELF-ADJUSTABLE ENDO-URETRAL DEVICE AND METHODS OF USE
IL189659A0 (en) Ikk inhibitors for the treatment of endometriosis
EP2049505A4 (en) ISOFORM SELECTIVE HDAC HEMMER
EP1965824A4 (en) METABOLITENE DERIVATIVES OF HDAC INHIBITOR FK228
PT2056814E (pt) Compostos de 2,5-di-hidroxibenzeno para o tratamento da psoríase
EP1888056A4 (en) USE OF LADOSTIGIL FOR TREATING MULTIPLE SCLEROSIS
GB0624187D0 (en) HDAC inhibitors
IL210489A0 (en) Use of hdac inhibitors for the treatment of hodgkin's disease
GB0515035D0 (en) Treatment of atherosclerotic conditions
IL201466A0 (en) Use of hdac inhibitors for the treatment of bone destruction
PT1962913E (pt) Radioimunoconjugado para cd66 humano para o tratamento de mieloma múltiplo
GB0602857D0 (en) The treatment of sialorrhoea
IL201439A0 (en) Use of hdac inhibitors for the treatment of melanoma
ZA200906906B (en) Use of HDAC inhibitors for the treatment of melanoma
EE200800070A (et) HDAC inhibiitorite kasutamine lmfoomide raviks
GB0621474D0 (en) Composition for the treatment of halitosis
ZA200801707B (en) IKK inhibitors for the treatment of endometriosis